Patents Assigned to Wyeth
  • ActRIIB FUSION POLYPEPTIDES AND USES THEREFOR
    Publication number: 20110250198
    Abstract: Methods and compositions for inhibiting growth and differentiation factor-8 (GDF-8) activity in vitro and in vivo are provided. The methods and composition can be used for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or glucose homeostasis.
    Type: Application
    Filed: December 10, 2010
    Publication date: October 13, 2011
    Applicant: Wyeth LLC
    Inventors: Neil M. Wolfman, Mary L. Bouxsein
  • SURFACE PROTEINS OF STREPTOCOCCUS PYOGENES
    Publication number: 20110243977
    Abstract: ?-hemolytic streptococci polynucleotides, polypeptides, particularly Streptococcus pyogenes polypeptides and polynucleotides, and antibodies of these polypeptides are described. The polynucleotides, polypeptides, and antibodies of the invention can be formulated for use as immunogenic compositions. Also disclosed are methods for immunizing against and reducing ?-hemolytic streptococcal infection, and for detecting ?-hemolytic streptococci in a biological sample.
    Type: Application
    Filed: January 24, 2011
    Publication date: October 6, 2011
    Applicant: WYETH LLC
    Inventors: Stephen Bruce Olmsted, Robert John Zagursky, Elliott Bruce Nickbarg, Laurie Anne Winter
  • NEUTRALIZING ANTIBODIES AGAINST GDF-8 AND USES THEREFOR
    Publication number: 20110243953
    Abstract: The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), in particular human antibodies, and antibody fragments, including those that inhibit GDF-8 activity in vitro and/or in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle or bone, or disorders of insulin metabolism.
    Type: Application
    Filed: December 7, 2009
    Publication date: October 6, 2011
    Applicants: Wyeth, Medlmmune Limited
    Inventors: Geertruida M. Veldman, Monique V. Davies, Kening Song, Neil M. Wolfman, Kristie Grove Bridges, Anne Field, Caroline Russell, Viia Valge-Archer
  • Drug combination useful for prevention of restenosis
    Patent number: 8029561
    Abstract: The current invention comprises an approach to solving the clinical problem of restenosis, which involves the administration of combinations of drugs to patients undergoing PTCA or stent implantation. In one embodiment of the invention, an antiproliferative agent such as rapamycin, vincristine or taxol is administered in combination with the antiinflammatory agent, dexamethasone, to patients systemically, either subcutaneously or intravenously. In another embodiment of the invention, the antiproliferative and antiinflammatory agents are bound in a single formulation to the surface of a stent by means of incorporation within either a biodegradable or biostable polymeric coating. Alternatively, such drug combinations could be incorporated into a stent constructed with a grooved reservoir.
    Type: Grant
    Filed: May 19, 2000
    Date of Patent: October 4, 2011
    Assignees: Cordis Corporation, Wyeth
    Inventors: Gregory A. Kopia, Gerald H. Llanos, Robert Falotico
  • Biosynthetic gene cluster for the production of a complex polyketide
    Patent number: 8030325
    Abstract: A polyketide synthase complex composed of polyketide synthase with 15 total modules, a non-ribosomal peptide synthetase with 1 module, and a cytochrome P450 hydroxylase is described. Also provided are novel Streptomyces species and methods of modified Streptomyces species. Further described are novel compounds, 36-ketomeridamycin, C9-deoxomeridamycin, and C9-deoxoprolylmeridamcyin and uses thereof.
    Type: Grant
    Filed: July 25, 2008
    Date of Patent: October 4, 2011
    Assignee: Wyeth LLC
    Inventors: Min He, John Hucul, Bradley Arnold Haltli, Melissa M. Wagenaar, Edmund Idris Graziani, Mia Summers, Kerry Kulowski, Kevin Pong, Xidong Feng
  • Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant
    Patent number: 8026276
    Abstract: Parenteral formulations of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl) -2-methylpropionic acid (CCI-779) are provided. One parenteral formulation contains CCI-779, an alcoholic co-solvent, and an antioxidant. Another parenteral formulation contains CCI-779, an alcoholic solvent, an antioxidant, a diluent solvent, and a surfactant. Processes for preparing parenteral CCI-779 formulations using a co-solvent concentrate are also provided.
    Type: Grant
    Filed: July 25, 2003
    Date of Patent: September 27, 2011
    Assignee: Wyeth LLC
    Inventors: Joseph T. Rubino, Victoria Siskavich, Maureen M. Harrison, Pooja Gandhi
  • Child Resistant Bulk Dose Dispensing Unit
    Publication number: 20110226772
    Abstract: Child-resistant bulk dose dispensing packaging unit, and a method for opening the packaging unit, including a container and a lid engaged with the container. The container includes a reservoir, an aperture at a top end of the reservoir, and a protrusion extending from a surface of the container. The lid engages with the container and slides between a closed position and an open position. The lid includes a top wall, a side wall extending down from an outer edge of the top wall, and a post configured to engage the protrusion at a first position when the lid is closed so as to keep the lid closed. At least a portion of the post extends substantially parallel to the side wall at a distance from the side wall. Pressing the side wall inward places the post at a second position, wherein at the second position the post is disengaged from the protrusion.
    Type: Application
    Filed: March 22, 2010
    Publication date: September 22, 2011
    Applicant: Wyeth LLC
    Inventors: Ari Tao Adler, Robert John McCaffrey
  • TREATMENT OF AMYLOIDOGENIC DISEASES
    Publication number: 20110229413
    Abstract: The invention provides preferred dosage ranges, maximum concentrations, average concentrations and monitoring regimes for use in treatment of Alzheimer's disease using antibodies to A?. The invention also provides monitoring regimes that as can assess changes in symptoms or signs of the patient following treatment.
    Type: Application
    Filed: October 17, 2008
    Publication date: September 22, 2011
    Applicants: JANSSEN ALZHEIMER IMMUNOTHERAPY, WYETH LLC
    Inventors: Ivan Lieberburg, James Callaway, Michael Grundman
  • Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
    Patent number: 8022216
    Abstract: The present invention relates to maleate salt forms of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, methods of preparing crystalline maleate salt forms, the associated compounds, and pharmaceutical compositions containing the same. The maleate salts are useful in treating cancers, particularly those affected by kinases of the epidermal growth factor receptor family.
    Type: Grant
    Filed: October 15, 2008
    Date of Patent: September 20, 2011
    Assignee: Wyeth LLC
    Inventors: Qinghong Lu, Mannching Sherry Ku, Warren Chew, Gloria Cheal, Anthony F. Hadfield, Mahmoud Mirmehrabi
  • MULTI-VITAMIN AND MINERAL NUTRITIONAL SUPPLEMENTS
    Publication number: 20110223250
    Abstract: The invention provides a nutritional supplement which includes micronutrients to facilitate reduction of cholesterol, and/or reduction of homocystein and/or reduction of low-density lipoprotein-cholesterol (LDL-C) oxidation in humans. In one embodiment the supplement is a multi-vitamin, a mineral supplement which includes at least one component known to reduce cholesterol. The invention further provides a method for tableting one fourth to one half of the daily effective dosage of a phytosterol containing nutritional supplement in a practical sized tablet and a method for reducing blood cholesterol in humans.
    Type: Application
    Filed: February 9, 2011
    Publication date: September 15, 2011
    Applicant: Wyeth LLC
    Inventors: William Bubnis, Richard Cotter, Paul W. Herman, Judith Moreines, Scott W. Poxon, Bruce W. Sutton, Jeffrey V. Vernon, Denise L. Walters, Michael G. Williams, Neil Wittenberg
  • Polymorph Form II of Tanaproget
    Publication number: 20110212953
    Abstract: Tanaproget polymorph Form II, processes for preparing tanaproget polymorph Form II, pharmaceutical compositions including tanaproget polymorph Form II, micronized tanaproget polymorph Form II, and processes for converting Form II to tanaproget Form I are provided. Also provided are methods of contraception, hormone replacement therapy, stimulation of food intake and treating or preventing uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, or carcinomas and adenocarcinomas comprising administering polymorph Form II to a mammalian subject.
    Type: Application
    Filed: May 12, 2011
    Publication date: September 1, 2011
    Applicant: Wyeth LLC
    Inventors: Marc Sadler Tesconi, Mannching Sherry Ku, Yan Xu
  • METHODS OF MODULATING IL-22 AND IL-17
    Publication number: 20110212099
    Abstract: The present application provides methods of modulating immune responses by using IL-22 in combination with at least one of IL-17A, IL-17F, or IL-23 or by using an IL-22 antagonist, such as an antibody or a soluble receptor or a binding protein, in combination with an antagonist of at least one of IL-17A, IL-17F, or IL-23
    Type: Application
    Filed: March 15, 2011
    Publication date: September 1, 2011
    Applicant: Wyeth LLC
    Inventors: Spencer C. LIANG, Lynette A. Fouser, Margot O'Toole
  • Use of antioxidants to prevent oxidation and reduce drug degradation in drug eluting medical devices
    Patent number: 8007737
    Abstract: Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. In each of these instances, antioxidants are utilized to prolong product integrity.
    Type: Grant
    Filed: April 14, 2004
    Date of Patent: August 30, 2011
    Assignee: Wyeth
    Inventor: Roy R. Fennimore, Jr.
  • Thermal covering
    Patent number: 8002721
    Abstract: The present invention is directed to a thermal covering that delivers consistent therapy to a portion of a user's hand-wrist area, is easy to use and apply to the body, and is securely positionable on the body. The thermal covering can be entirely disposable after one use. The thermal covering can also have a disposable component and a reusable component that can be packaged individually together as a kit.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: August 23, 2011
    Assignee: Wyeth LLC
    Inventors: Donald Stephen Bretl, Mary Elaine Freeland, Kyle William Harris, Richard W. Pack, Angela Marie Reed
  • Cyanopyrrole containing cyclic carbamate and thiocarbamate biaryls and methods for preparing the same
    Patent number: 8003784
    Abstract: Methods for preparing cyclic carbamates and thiocarbamates containing cyanopyrrole moieties and of the formula are provided. Z are the same or different and are H, optionally substituted C1 to C6 alkyl, or CORA; RA is H, optionally substituted C1 to C6 alkyl, optionally substituted C1 to C6 alkoxy, or optionally substituted C1 to C6 aminoalkyl; Q are the same or different and are H, OH, NH2, CN, halogen, optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkenyl, optionally substituted C1 to C6 alkynyl, optionally substituted C1 to C6 alkoxy, optionally substituted C1 to C6 aminoalkyl, or CORB; and RB is H, optionally substituted C1 to C6 alkyl, optionally substituted C1 to C6 alkoxy, or optionally substituted C1 to C6 aminoalkyl.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: August 23, 2011
    Assignee: Wyeth LLC
    Inventor: Bogdan Kazimierz Wilk
  • Calcium phosphate delivery vehicles for osteoinductive proteins
    Patent number: 8003133
    Abstract: A composition for delivery of osteogenic proteins is disclosed. The composition comprises an osteogenic protein, a calcium phosphate material as a carrier, and an effective amount of an effervescent agent. Methods of making the compositions and methods of using the osteogenic compositions to treat osteoporotic and/or osteopenic bone are also disclosed.
    Type: Grant
    Filed: September 23, 2009
    Date of Patent: August 23, 2011
    Assignees: Wyeth LLC, Etex Corporation
    Inventors: Rebecca Li, Howard Seeherman, Aliassghar Tofighi
  • Treatment of cerebral amyloid angiopathy
    Patent number: 8003097
    Abstract: The invention provides improved agents and methods for treatment of cerebral amyloid angiopathy (CAA) and methods to effect prophylaxis of CAA. The methods can treat CAA concurrently with Alzheimer's disease or separately. The methods can effect prophylaxis of CAA concurrently with Alzheimer's disease or separately. The methods involve administering antibody that is specific for the N-terminus of A? or an agent that can induce such an antibody.
    Type: Grant
    Filed: July 28, 2008
    Date of Patent: August 23, 2011
    Assignees: Janssen Alzheimer Immunotherapy, Wyeth LLC
    Inventors: Sally Schroeter, Kate Dora Games, Wagner Zago
  • MULTIVALENT PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE COMPOSITION
    Publication number: 20110201791
    Abstract: An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection. Methods for making an immunogenic conjugate comprising Streptococcus pneumoniae serotype 19A polysaccharide are also provided in which the serotype 19A polysaccharide is co-lyophilized with a carrier protein and conjugation is carried out in dimethyl sulfoxide (DMSO) via a reductive amination mechanism.
    Type: Application
    Filed: April 26, 2011
    Publication date: August 18, 2011
    Applicant: WYETH LLC
    Inventor: A. Krishna Prasad
  • Glutamate aggrecanase inhibitors
    Patent number: 7998965
    Abstract: The present invention relates to modulators of metalloproteinase activity.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: August 16, 2011
    Assignee: Wyeth LLC
    Inventors: Phaik-Eng Sum, Jerauld Stanley Skotnicki, Steve Yik-Kai Tam, Tarek Suhayl Mansour, David Brian How, Joshua James Sabatini, Jason Shaoyun Xiang, Eric Feyfant
  • Methods and compositions for selectin inhibition
    Patent number: 7994333
    Abstract: The present invention relates to the field of anti-inflammatory substances, and more particularly to novel compounds that act as antagonists of the mammalian adhesion proteins known as selectins. In some embodiments, methods for treating selectin mediated disorders are provided which include administration of compound of Formula I: wherein the constituent variables are defined herein.
    Type: Grant
    Filed: November 7, 2008
    Date of Patent: August 9, 2011
    Assignee: Wyeth LLC
    Inventors: Neelu Kaila, Silvano L. Debarnardo, Kristin M. Janz, Raymond T. Camphausen, Patricia Ward Bedard, Adrian Huang